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then-test scores only in the item of NV (P < 0.01). This was
consistent in the additional analyses divided into the two RCT
arms on the whole. CONCLUSIONS: The results of this study
suggest that we can rely on the QOL assessment results in RCTs
without worrying too much about RS.
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OBJECTIVES: The objective of this analysis was to examine the
impact of ustekinumab on health related quality of life (HRQoL)
in psoriasis patients. METHODS: 766 patients were enrolled
in the PHOENIX I trial. Patients were randomized to placebo,
ustekinumab 45 mg, or ustekinumab 90 mg. Patients received
ustekinumab at baseline, week 4, and q12w thereafter. Patients
randomized to placebo received placebo at baseline and week 4,
and ustekinumab 45 mg or 90 mg after cross-over at week 12.
HRQoL were assessed using the SF-36 and Dermatology Life
Quality Index (DLQI). RESULTS: Baseline SF-36 and DLQI
scores were similar among treatment groups with a mean PCS
score of 47.9, mean MCS score of 49.8, and mean DLQI score of
11.5. Compared with the placebo group, patients in each usteki-
numab group had signiﬁcantly greater improvements from base-
line in both the PCS (2.0 and 3.2, vs. -0.5, p < 0.001) and MCS
scores (2.1 and 2.5 vs. -1.3, p < 0.001) at week 12. All 8 domains
of the SF-36 showed statistically signiﬁcant improvements
(p < 0.05) in the combined ustekinumab group versus placebo at
week 12. At week 12, themean change from baseline in DLQIwas
-8.0 for the 45 mg group and -8.7 for the 90 mg group versus
-0.6 for the placebo group (each p < 0.001 vs. placebo). A greater
proportion of patients in each ustekinumab group than in the
placebo group achieved a clinically meaningful improvement
in PCS and MCS scores (5-point improvement), and a DLQI
score of 0 or 1 at week 12. These improvements observed in the
ustekinumab groups were maintained through week 40. Patients
in the placebo groupwho crossed-over to ustekinumab at week 12
achieved improvements in PCS, MCS and DLQI scores at week
40 that were similar in magnitude to those observed in patients
initially randomized to ustekinumab. CONCLUSIONS: Usteki-
numab treatment signiﬁcantly improves overall and disease-
speciﬁc quality of life in moderate to severe psoriasis patients.
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OBJECTIVES: To demonstrate the pertinence of using thermal
therapy in terms of quality of life. METHODS: During the 2005
and 2006 seasons, a generic scale (SF-12) and a speciﬁc scale
(DLQI—Dermatology Life Quality Index) were ﬁlled in by each
patient when they arrived at the Avène hydrotherapy center
(consultation on arrival), at the end of the thermal therapy (week
3), but also at 3 and 6 months after the end of the therapy.
RESULTS:These results took into account the 262 questionnaires
from patients suffering from psoriasis who ﬁlled in the self-
questionnaires on arrival. The average age of the subjects was
52.2  13.8 years. The gender ratio was in favour of men (55.3%
vs 44.7%). The average age of the subjects at the time of diagnosis
was 32.1  16.9 years. 66.0% of the subjects considered that
their dermatosis had deteriorated “their daily life”, 49.6% “their
health” and 49.2% “their leisure activities”. Following the 3
weeks of treatment these feelings had strongly diminished, there
were respectively only 35.2%, 26.6%and 30.5%who thought so.
The DLQI score on arrival was 26.1  20.2; following therapy
it was 10.0  10.5. The evaluation of the DLQI score was com-
pared to the score obtained on arrival, showing a signiﬁcant
improvement in quality of life at 3 weeks, sustained improvement
at 3 months and perpetuation of the effect at 6 months (p < 0.05).
These results showa signiﬁcant improvement in themental dimen-
sion of the SF-12 (MCS-12 = 39.0 on arrival to 42.5 at following
therapy). CONCLUSIONS: This study conﬁrms the alteration in
the quality of life of patients suffering frompsoriasis and its impact
on daily life. The results conﬁrm the improvement in the patients’
quality of life following the therapy, sustained improvement at 3
months, and perpetuation at 6 months.
PSS43
ATOPIC DERMATITIS ANDTHERMALTHERAPY: EVALUATION
OF MEDICAL SERVICE
Boussetta S1,Taieb C2
1Pierre Fabre, Boulogne, France, 2Pierre Fabre, Boulogne, FRANCE,
France
OBJECTIVES: To demonstrate the pertinence of using thermal
therapy in terms of quality of life. METHODS: During the 2005
and 2006 seasons, a generic scale (SF-12) and a speciﬁc scale
(DLQI—Dermatology Life Quality Index) were ﬁlled in by each
patient when they arrived at the Avène hydrotherapy center
(consultation on arrival), at the end of the thermal therapy (week
3), but also at 3 and 6 months after the end of the therapy.
RESULTS: These initial results took into account the 174 ques-
tionnaires from patients suffering from atopic dermatitis. The
average age of the subjects was 36.4  14.7 years. The gender
ratio was largely in favour of women (70.1% vs 29.9%). The
median age of the subjects at the time of diagnosis was 16.0
years. Women were diagnosed earlier than men, with a median
diagnosis age of 8.0 years for women and 20 years for men.
72.1% of subjects considered that their dermatosis had deterio-
rated “their daily life”, 58.9% “their health” and 60.0% “their
leisure”. Following the 3 weeks of therapy these feelings had
strongly diminished, and respectively only 44.3%, 34.8% and
35.3% thought so. The DLQI score on arrival was 32.4  22.7
The evaluation of the DLQI score was compared to the DLQI
score obtained on arrival, showing a signiﬁcant improvement in
quality of life at 3 weeks sustained improvement at 3 months and
perpetuation of the effect at 6 months. No signiﬁcant improve-
ment in either the mental dimension or the physical dimension of
the SF-12 were observed. CONCLUSIONS: This study conﬁrms
the alteration in the quality of life of patients suffering from
atopic dermatitis and its impact on daily life. The results conﬁrm
the improvement in the patients’ quality of life following the
therapy, sustained improvement at three months, and perpetua-
tion at six months.
PSS44
ATOPIC DERMATITIS & PSORIASIS: CROSS-EVALUATION OF
QUALITY OF LIFE
Boussetta S,Taieb C
Pierre Fabre, Boulogne, France
OBJECTIVES: The objective of this project was to conduct a
cross-evaluation of the quality of life of patients suffering from
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